2020.10.27 (화)

  • 맑음동두천 17.0℃
  • 맑음강릉 21.5℃
  • 연무서울 17.6℃
  • 연무대전 18.5℃
  • 연무대구 18.7℃
  • 맑음울산 19.6℃
  • 구름많음광주 ℃
  • 맑음부산 21.8℃
  • 구름많음고창 18.9℃
  • 구름많음제주 18.9℃
  • 맑음강화 17.5℃
  • 맑음보은 14.7℃
  • 맑음금산 18.0℃
  • 구름조금강진군 20.0℃
  • 맑음경주시 19.4℃
  • 맑음거제 19.4℃
기상청 제공

종양내과

전이성 GIST에 대한 표준요법

서울아산병원 종양내과 박숙련 교수

URL복사


* 출처 : 서울아산병원

제13회 GIST환우 모임
2016년 5월 28일 / 서울아산병원 대강당


서울아산병원 종양내과 
박숙련 교수

진료과: 종양내과,암병원,간센터,식도암센터,위암센터
전문진료분야: 위암,간암,식도암,GIST

학력 사항
서울대학교 의학 학사
서울대학교 의학 석사
서울대학교 의학 박사

교육 및 연구 경력
현)울산의대 서울아산병원 종양내과 부교수

주요 업적 
<논문>
A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed After Cisplatin Plus Either S-1 or Capecitabine.

A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival.

A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas.

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers.

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.

Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).

Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).

FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.

관련기사



배너
배너